Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"I definitely could have blended right in with those guys."
In fact, believe it or not, I love to sing in choirs, and some of 'John's Boys' heard some of my country covers, and wanted me to join the group. I declined, because they wanted to re-imagine the choir, and become the ChippenWales.
Well, I did say, believe it, or not.
I initiated this thread by focusing on lenzilumab's strong binding affinity and slow off-rate. I think Ivermectin can be a useful therapeutic against covid (it seems to actually bind the covid spike protein), instead of binding GM-CSF. But it seems that as soon as Ivermectin is ceased, all the symptoms patients were suffering come roaring back. It's just an issue I would like to know more about, if regulators continue to keep lenzilumab on the shelf.
Additionally, there is an issue regarding significantly reduced energy levels. That affects me, and I've got a couple acres of land I've got to maintain this spring. I thought it was my being lazy, progressing to just becoming lazier. But this is now ridiculous, and even somewhat debilitating. That's another reason I want to look into this subject. I had already practically self-diagnosed myself as having Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Symptoms can include problems thinking and concentrating, which I try to alleviate with staying engaged here (just don't make me read another 10-Q, or anything else from a bankruptcy court filing), and practically becoming house-bound (but I've always been a homebody).
Anyway, thank you for letting me know that Humanigen doesn't own the lenz IP. I don't anticipate that will adversely impact the safety and efficacy of lenz. Nor do I think it will result in one less short share being recalled. When that happens, I might even get to enjoy a curative dose of adrenaline!
Both Sanofi and Novavax have been tending to details regarding Beneficial Ownership Statements.
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001121404&owner=include&count=40&hidefilings=0
https://www.sec.gov/cgi-bin/browse-edgar?CIK=0001000694&owner=exclude
How does it benefit Taran to own the IP to a drug that has a strong binding affinity (25 pM) and a slow off-rate?
For further study:
"Lenzilumab is a novel Humaneered® anti-human GM-CSF monoclonal antibody that binds directly to the GM-CSF and blocks further signalling through its receptor. It also showed strong binding affinity (25 pM) and a slow off-rate
https://link.springer.com/article/10.1007/s10787-021-00903-x
Ivermectin, and it's binding of the spike protein
In my initial reply to your post, I failed to acknowledge the first clause in your question. The answer, despite my earlier language in an unrelated post, is that, yes, all is well with me.
However, someone I care about is having some health issues, and I wanted her to see the videos in a couple of my posts. She had told me that she has had some boosters, following a Pfizer vaccine. I have never had a post rejected on this site, AND blocked on X. But, there's a first time for everything. So I had to email the videos to her, and hope that she can open the videos from her email, or that she finds those videos in other of my postings here.
You also expressed some question about Humanigen's right to use lenz. And I see others here also concerned about our future.
For years, I have talked about the "script" written in our company's history. In 2015, as now, the company was forced into a CH11 bankruptcy, just as we were again forced to do. And too many shareholders are failing to continue looking to our past, to project our future. This wasn't The End of the company in 2015, and it isn't The End of the company now, either.
Shareholders need to realize that Humanigen remains on track toward accomplishing their goals. If there has been a change, I think we may see management rely more on foreign regulatory approval. Certainly, we are seeing the British parliament address issues such as excess deaths from mRNA vaccines. This has got to force the MHRA to abandon the status quo, and to consider granting approval of lenz to treat covid.
Other treatments could even capitalize on plant-based alternatives to controlling cytokine release syndrome.
https://www.nasdaq.com/press-release/gb-sciences-targets-covid-19-treatment-as-omicron-variant-arrives-2021-12-06
I think we may be in an ETF with them (but don't ask me to explain that). All I could do was to buy a small number shares in the company.
Finally, to me, there was an unknown distinction between SAR-S CoV-2 coronavirus in nucleocapsid proteins, caused by the virus, versus covid spike proteins caused by the mRNA vaccines. I really hope that a study has been done focused on the reduction of nucleocapsid covid proteins after administering lenz.
The only source I have for this observation is Bret Weinstein. I've hear him comment about the Chinese immigrants in various interviews, and you can hear what he tells Joe Rogan from the 4:05 minute mark.
MP Andrew Bridgen addresses British Parliament on the issue of excess deaths due to mRNA vaccines.
At the 7:30 minute mark, he quotes an expert opinion that the cause of these excess deaths has to be the experimental mRNA vaccines.
A lot of our presentations are no longer available, which is where I thought this was communicated. I'll keep looking. I've seen so many slides recently with covid spike proteins, and SARs-CoV2 nucleocapsid proteins, throughout the body, I may have mis-learned how those proteins get there.
It's very alarming that the Chinese illegal immigrants, who cross the border just as other foreign nationals are crossing the border, apparently segregate themselves while making the trek here, and seem to have their own camp sites on the trail, such as they have in San Vicente, in the Darien Gap. Non-Chinese are prohibited from even entering that camp site, and the Chinese do not communicate with the others. I haven't mentioned that earlier, because I only have a single source for that information. But my point is that I think this represents a serious threat of biological attack to our country. Yes, we have only found one (combined from two) illegal biotech labs being operated by Chinese nationals on our soil, and we only have two Chinese balloons (which can be equipped with biological dispersion capability) that have been observed in our airspace. But we also have illegal immigrants from the Middle East entering our country. The point is, that we cannot tolerate the lack of a true covid vaccine, or not having a safe and effective covid therapeutic that will also prevent rebound infections.
Covid will never be over. But lenz can prevent covid pneumonia infections in the future.
We have to assume that Humanigen has a license to use lenz, since Taran bought the IP...or, we just need to see the merger or business combination between Taran and Humanigen. I think that Humanigen has every intention to use lenz for covid, or Durrant would have simply bought out Humanigen.
Yes, I think that WAS the Big Pharma/Government objective, to keep us dependent on them.
But, too much evidence is surfacing that the mRNA vaccines (maybe even the adenovirus ones), are causing excess deaths. And I hope that Durrant is going to capitalize on the British Parliament's intent to put a stop to that, and the MHRA may finally approve lenz for covid.
Yes and no, ben. Durrant has gotten FDA approval of many drugs throughout his career, including several that proved to be blockbusters. So I think that demonstrates that he is actually an expert at knowing "what it takes to get a drug approved."
But that also means that regulators can't bullshit him. Yet, that is what they are trying to do. So Durrant knows what he has to do now.
The thing I like about Novavax is that they got regulatory approval from countries all around the world, before trying to get FDA approval in the US. The CEO they had was smart enough to do that, but fell short of managing operations afterwards. So they have a new CEO, and he seems better at managing operations. And I hope they end up partnering with Humanigen, and use lenz as a vaccine enhancement.
But we need lenz approved by a regulator, and I think the UK will finally be the regulator that approves lenz? Why? Because they have to.
My focus lately has been been on the UK's response to reality. I've been showing videos that graphically demonstrate that reality (for my reference, I'm talking about post numbers 42034 and 42035). Still, there is enough video evidence that I've been permitted to show that Humanigen's/Taran's lenz should be used in place of the mRNA vaccines. The proof is incontrovertible.
Not only are doctors/embalmers seeing novel presentations of the deadly blood clots they are finding post-mortem, actuaries and researchers are substantiating the physical evidence with statistical evidence. They are demonstrating multiple findings, such as significant excess deaths, in those patients who had mRNA vaccines.
In Durrant's post (which I still can't find) about Taran's objectives going forward, he didn't specifically mention covid. I hope, however, that's because Humanigen may continue that effort after they recall their loaned shares, and therefore have the funds to proceed.
This is what management did.
"Effect of CRP<150 mg/L on SWOV and secondary endpoints in
LIVE-AIR
In participants with baseline CRP <150 mg/L, lenzilumab
improved the likelihood of SWOV compared with placebo
(HR: 2.54; 95% CI 1.46 to 4.41; nominal p=0.0009; table 2a,
figure 2B). Separation of the survival curves appeared earlier
than in the overall population and followed a similar pattern
as the overall population thereafter (figure 2B). The number
needed to treat (NNT) was nine for this group compared with
17 for the overall population (table 2A). SWOV, in response to
lenzilumab treatment, was similar to placebo in participants with
CRP ≥150 mg/L at baseline (table 2A and figure 2C). The NNT
for this group was 37 (table 2A)"
https://thorax.bmj.com/content/thoraxjnl/early/2022/07/05/thoraxjnl-2022-218744.full.pdf
How can you look at those results, and NOT blame the FDA for withholding our EUA? That shows stellar performance of lenzilumab, captured brilliantly by the LIVE-AIR trial investigators.
The disgrace belongs to people like us, for failing to demand accountability from our government, who focuses on "government of the people," and never has to worry about that governance being exercised "by the people, and for the people." All discretionary authority should be rescinded from government agencies.
But, in our case, management didn't intend to treat covid, when they took over the company, which was almost 3 years before covid arrived. When the disease hit, management had no choice but to put lenzilumab into the fight. They were right to do so. They are doctors bound by an Hippocratic Oath.
"I shall work with my profession to improve the quality of medical care and to improve the public health, but I shall not let any lesser public or professional consideration interfere with my primary commitment to provide the best and most appropriate care available to each of my patients."
Lenzilumab is the only therapeutic that binds GM-CSF and prevents the virus from infecting the intended receptor cells. And as importantly, it imbues an appropriate immune response to prevent future infections. Even now, our MOA offers the most effective solution to fight covid.
Where would the world be right now, if the FDA had approved our EUA application in May of 2021?
https://ir.humanigen.com/English/news/news-details/2021/-Humanigen-Submits-Application-to-FDA-for-Emergency-Use-Authorization-for-Lenzilumab-in-COVID-19/default.aspx
Instead, where are we now? We have covid deaths ranging from 7M - 20M, by some estimates. AND, we have no safe and effective TRUE vaccine, nor do we have a safe and effective therapeutic, both of which we would likely have, if lenz was approved. This is no time to still our voices, and surrender. Preventable deaths are occurring every single day.
Big Pharma provides 65% of FDA funding, and 86% of MHRA funding.
This is according to Dr. Aseem Malhotra, as he claimed in an interview with Tucker. If this is true, how can a small biotech like Humanigen, even with a mega-blockbuster drug, which lenzilumab is, ever get Regulatory approval?
See minute mark 23:50 of the video linked below.
Andrew Bridgen, MP, requests meeting with Scotland Yard, "...regarding, "Very serious criminal offences to name but a few, Misconduct in Public Office, Misfeasence in Public Office, Gross Negligent Manslaughter, Corporate Manslaughter, Fraud, Murder, Manslaughter and Grievous Bodily Harm,.." and more, regarding the Coronavirus pandemic and vaccination program.
https://www.linkedin.com/posts/andrewpearce_andrew-bridgen-mp-abridgen-on-x-activity-7171096018267131904-dnT4
This is of significant relevance to Humanigen, as an appropriate Regulatory response would include the authorization and approval of lenzilumab to treat covid prophylactically as a vaccine adjuvant, and therapeutically.
The safety and efficacy of lenz has resulted in meeting the primary endpoint in the company-sponsored LIIVE-AIR trial, and the results have been peer-reviewed by both Lancet and Thorax.
https://www.humanigen.com/
Novel presentations of blood clots, including long white fibrous strands of blood clots, are being discovered in the bodies of patients who had multiple mRNA vaccinations. They have also resulted in covid spike proteins located in organs such as the brain and heart. as shown in the following videos.
Edit "...6.9M American,,," should have read 6.9M worldwide deaths. Americans accounted for 1.123M of the total deaths as of one year ago.
https://coronavirus.jhu.edu/map.html
Where have you been, OneDay? What I saw yesterday was hardly a sign of short covering.
"The short sale volume percent (not short interest) for stock ticker HGENQ is 99.74% on Mar 08, 2024. The short sale volume is 190,171. The total volume is 190,671."
http://shortvolumes.com/?t=hgenq
Maybe some brokerage was caught charging a client short interest, without having secured a locate.
Thank you, JA3. I am of Irish, German, and Welsh descent, myself. I was glad to see a male choir from Wales perform on Britain's Got Talent last year. I thought BGT judge Amanda Holden was simply going to melt, just listening to them. I definitely could have blended right in with those guys, without buying a new wardrobe. I wonder if I had family in that group, LOL! I just felt right at home with them.
"Moderna pays US government $400M 'catch-up payment' under new COVID-19 vaccine license
By Eric SagonowskyFeb 24, 2023"
https://www.fiercepharma.com/pharma/moderna-pays-us-government-400m-catch-payment-under-new-covid-19-vaccine-license
Wut da problem is?
Good to see you, JA3. Your link just took me a Linked-In sign in page. I don't have a Linked-In account.
It made sense to me, as I said in a previous post, to transfer the IP rights to Taran to safeguard the IP in the event that the bankruptcy court judge converted the case to CH7, in which case the IP would have been included in the sale.
Did Humanigen have entitlement to sells revenue earned by our Korean partner, simply because we owned the IP? No.
Nor would Taran have entitlement to sells revenue earned by Humanigen.
We just haven't see the details yet regarding licensing, or a possible merger. What we DO know is that Taran did not submit a tender offer to buy Humanigen, which is the only way Taran could claim sells revenue. But again, as Asset Purchase Agreement is not a buy-out.
Well, first of all, I don't see a revenue stream for Taran. It will be Humanigen's revenue. And did you see Durrant resign as Humanigen's CEO? I didn't.
The in-process structural change has not diminished Humanigen's capacity to execute their business plan. I'm not worried at all. In act, I'm excited to see how all the pieces will fit together.
The bankruptcy judge did not share your pessimistic view.
It's a very exciting time for us, Jim!
In regards to my oft-wondered-about covid pneumonia reinfection rate in lenz-treated patients, which I think could be an absolute game-changer for Humanigen's lenzilumab, I learned last night that I may again have to re-phrase my question, and likely have to ask more than just one question. But just to get started, let me ask the following.
In patients diagnosed with covid pneumonia, and treated with lenzilumab, what is the recurrence rate of those patients presenting with SARS-CoV-2 nucleocapsid proteins after treatment? (I'll have to pin this post to remember how to ask that question).
As my question was originally phrased, I didn't know better than to exclude subsequent presentations of covid found in spike proteins. The studies I reviewed last night demonstrate that covid in the spike proteins has no relation to how well lenz prevents future infections. Rather, as I read the studies I will link, covid found in spike proteins is mRNA vaccine-induced. So lenz-treated patients who subsequently present with covid spike proteins, have no bearing on the efficacy of lenz.
Attached is an autopsy report of a 76 year old man, which was used as a case study. The patient had no history of covid, but the pathologist found covid spike proteins leading to the heart and brain. It's a fascinating study which, along with a different, un-related discussion concerning San Vincente in the Darian Pass, kept me up all night reviewing.
The presentation gets off to what might be perceived as a slow start, but don't fast forward past the 11 minute mark, of the 28 minute video.
Interesting niche. But I don't see anything about production turnaround, and it appears that their CAR-T is designed to enhance mitigation of CCR-9. I think Gracell's 24 hour turnaround for CAR-T is a much better, even revolutionary, alternative, which I hope that lenz is a part of making that happen.
I see that they also provide CRISPR services. I think that lenz was developed with that gene-editing technology. But even so, I'm not comfortable with it, generally. And I see that GenScript also provides mRNA solutions, and I am becoming increasingly wary of that.
Lots and lots of potential with those technologies, but way too much opportunity for abuse of those capabilities.
https://www.genscript.com/?src=google&utm_source=google&utm_medium=cpc&utm_campaign=GenScript-ECPC_NA&jiraid=12194&gad_source=1&gclid=EAIaIQobChMIzsnPnL_ihAMVGy7UAR2UUQsxEAAYASAAEgJy3vD_BwE
Do you have a minute? Do you have 51 minutes?
I had never heard of Sharyl Attkisson, or her "Full Measure" weekly broadcast program, but I was fortunate enough to have just finished watching her program on "The Covid Clots," and I highly recommend that you watch it. It so happens that I am scheduled for an exam by my vascular surgeon on Friday, because it has been a year since he did the angioplasty/atherectomy on my leg artery. And I'm curious to see if he is familiar with the information I just learned about covid clots.
You brought this issue up last month, Jim
February 14, 2024
Isn't HGEN bankrupt? how do HGEN share holders have any chance at success? I was under impression that assets would be sold off and HGEN stock worth nothing now.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173844576
and I gave you my thoughts on this subject at that time
02/14/24
Hi, Jim,
Welcome to the room, and to Ihub.
If Durrant had filed a Chapter 7 bankruptcy, shareholders would have been wiped out.
But Durrant filed a reorganization bankruptcy under Chapter 11, which allows for the share structure to remain intact.
Here are a couple of articles about our previous bankruptcy, when the company was known as Kalobios, before restructuring.
https://moxreports.com/kbio-infinity-squeeze/
https://www.globenewswire.com/news-release/2017/07/27/1063782/0/en/KaloBios-To-Change-Company-Name-To-Humanigen-Inc.html
I'm looking for management to recall their loaned shares once again, and to cause yet another massive short squeeze.
https://investorshub.advfn.com/boards/replies.aspx?msg=173844576
What right does Taran have to recall the loaned shares? Did they loan any of those shares? What clinical trial relationships does Taran have with Humanigen's partners, working on bringing lenz to market for CMML, or aGvHD, or Covid, or for any of Sanofi's oncology or asthma indications? Taran's CEO Durrant could make Humanigen's CEO Durrant sign a licensing agreement, which he may have done already, if that would alleviate your concern.
But, Taran did not buy Humanigen. I think Humanigen remains on track with all of their on-going work, and the pending results of all that work are what shareholders have to look forward to accomplishing. If you think I'm missing something, maybe I am, in which case please inform me of what that is.
Is the Sanofi spin-off of their healthcare division designed to partner with Humanigen on the asthma market, and more?
According to Humanigen's Featured Presentation, "...historical clinical results could provide basis for global partnering discussions."
asthma mentioned on five slides in the chart deck
https://ir.humanigen.com/English/events-and-presentations/default.aspx
Does Sanofi think that lenz could do better than their Regeneron partner, using Dupixent? Or is Sanofi looking to expand their supply chain?
https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-fda-approved-first-and-only-treatment
There are worse problems to have than trying to figure out what will be the most valuable entity for Humanigen shareholders 🙂. You make some good points and I can understand your enthusiasm, which I share, for our success in Australia.
But, if the loaned shares are recalled, chances are it will be with news, and Humanigen's value could skyrocket well beyond the value of their subsidiaries or Taran, if that news is related to covid prevention/treatment authorization. And in that regard, I now see news from the UK Ministers accusing the Health Secretary, "...of withholding data that could link the Covid vaccine to excess deaths, and criticised a “wall of silence” on the topic.
A cross-party group has written to Victoria Atkins to sound alarm about the “growing public and professional concerns” at the UK’s rates of excess deaths since 2020."
https://www.yahoo.com/news/health-secretary-urged-release-data-181513423.html
I'm disappointed that the UK regulators did not act independently and much earlier to approve lenz for covid. So I'm glad to see pressure building on them in this regard. I think a study of lenz patients could actually show "decreased deaths" and negligible (or at least show a statistically significant lower level) of covid pneumonia reinfections.
You can never be sure how a bankruptcy court judge is going to rule, even with guys like Barliant (?) helping the company through the process. I appeared once in a corporate bankruptcy case, where the issue concerned naked shorting. The company was being naked shorted tens of millions of shares everyday, even though they were on the Failure-to-Deliver (FTD) list. The judge told me that he thought I (shareholders) had a case. But he couldn't see how naked shorting negatively impacted the issuer. I was dumb-founded, and I mean literally.
So, I can see how transferring intellectual property rights to Taran could have been a safeguard, pending how the judge ruled.
Beyond that, in my opinion, it has made a lot of sense to use Dale's entities as we have, broadly, as what I call our financing arm. I hope, going forward, that we continue to segregate our financing and operational activities, in the manner that we have. But I have to think that the value of Humanigen's shares is a reflection of the value of our intellectual property, and I expect that issue will be addressed as you mentioned, either by way of exclusive licensing, or with a potential merger through subsidiaries of Humanigen and Taran.
"COVID-19 remains a danger, especially to older people and those with underlying medical conditions. There are still more than 20,000 hospitalizations and more than 2,000 deaths each week due to the coronavirus, according to the CDC. And people 65 and older have the highest hospitalization and death rates."
https://www.yahoo.com/news/older-us-adults-another-covid-191550624.html
No, thanks. I'll have lenz, please.
You're right, eb.
And there's so much going on. Today, for example, Baudax filed a CH11. Will this give us the opportunity to bid on Tera-Immune?
https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/1780097/000119312524049000/d800225d8k.htm
And Sanofi's notice of appointing 3 Independent Directors yesterday, having already announced plans to spin-off their healthcare business, suggests preparations to ready the spin-off for Nasdaq listing.
https://www.sec.gov/Archives/edgar/data/1121404/000119312524047460/d702412dex993.htm
And as Preciouslife1's article informed us today, "Novavax expects full-year 2024 revenue to come in between $800 million and $1 billion. That forecast reflects an expected $500 million to $600 million in revenue from advanced purchase agreements and $300 million to $400 million from commercial market product sales, royalties and other revenue from the company’s “partner-related activity.”
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173936647
"What will be left in Humanigen ?"
If our float is as once reported, 229M shares, I believe that 110M (~90% of our OS) of those shares could be owned by Humanigen. That might be a whole lot of nothing, at a share price of $0.0001, or so, and no regulatory authorizations or approvals for lenz, and no customer demand.
But that could change instantly with news.
Pick a share price, if the brokerages are forced to buy-in shares, whether from a recall of the loaned shares, or a merger, and remember...the company owns most of the shares. So I'm hoping to sell some shares for about $200, especially if we're still on the Expert Market.
But, THERE'S SO MUCH POTENTIAL, that even if I can't sell at my target price, just our fundamental price could be in the $60 range ($8B, for example.) market cap, if we can get into the covid prevention market with the Novavax vaccine, and/or regulatory approval for CMML, not to mention a PRV, Humanigen could end up with a boat load of cash.
Hello, InfinitePhoenix4. Welcome to the room, and thank you for posting your first Ihub message here. I appreciate the thought you put into it.
I think it is very likely that lenz could receive it's first regulatory approval in Australia, to treat CMML. It's also possible that a Priority Review Voucher in the range of ~$100M could be awarded with that approval.
But Taran didn't buy Humanigen. Taran bought the intellectual property rights. Do you agree, because I don't think you do? Let's start there, if you want.
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1061258&projectCode=HUM&docketNumber=155&source=DM
I haven't given the document the full study it deserves, because I have total confidence in management. I am as confident in Dale's stewardship of Humanigen's shares, as I am in Durrant's purchase of the intellectual property rights. Besides, I think we will see a merger, anyway. So I don't foresee value being left behind, once the share structure and the intellectual property rights are rejoined (joined), by some means.
I hope this all becomes moot, but even more so, I also hope to see the recall of the loaned shares, in short order. But I do agree that our value lies in the intellectual property, and have said that, "To be honest, I think it would take a lot more study for me to feel that I have confidence in making a deduction about HOW these guys have navigated during this bankruptcy." I'm looking forward to the completion of our restructuring.
We're not at our destination.
I don't understand you guys. The bankruptcy was brilliantly designed and executed, and the CH11 was successfully achieved. Between the rights Humanigen retained by way of the Excluded Assets, and also having a foreign subsidiary unencumbered to maneuver, I don't know what we can't do, that needs to be done, as the restructuring is completed.
Company of interest Sanofi, who appears to have long ago converted their common shares of Kalobios into preferred shares, today released a 6-K regarding several of their mabs and clinical trials. Also included was a press release concerning the appointment of three new Independent Directors. I wonder if the new Independent Directors are being appointed to gain Nasdaq compliance in the US, ahead of the spin-off of their healthcare division.
https://www.sec.gov/Archives/edgar/data/1121404/000119312524047460/d702412d6k.htm
With Gracell having completed becoming a subsidiary of AstraZeneca, and deregistering their stock on Nasdaq, I'm going to replace them with Sanofi (SNY) as one of the stocks I watch for SEC filings.
Sanofi is showing several recent beneficial ownership filings.
https://www.sec.gov/cgi-bin/browse-edgar?CIK=0001121404&owner=exclude